Neuro-Oncology News

The FDA has approved an oral, small molecule MEK inhibitor for adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection.

Exposure to radiation from head or neck CT imaging increased risk for childhood brain tumors, according to results of a nationwide population-based study conducted in Finland.

The addition of temozolomide to radiation therapy prolonged OS for patients with both co-deleted and non-co-deleted grade 2 gliomas, according to study results.

An analysis of adults with malignant glioma revealed that men were diagnosed at a younger age and women had worse preoperative status, but researchers found no other sex-related differences or clinical advantage.

Chimeric antigen receptor T-cell therapy can reduce tumor burden and improve neurologic function for patients with certain brain and spinal cord cancers, a first-in-human clinical trial showed.

A shortened adjuvant chemotherapy regimen improved outcomes for infants with unilateral pathologic high-risk retinoblastoma, according to study results.

The addition of veliparib to adjuvant temozolomide failed to improve OS for patients with newly diagnosed, MGMT-hypermethylated glioblastoma, according to randomized phase 2/phase3 study results.

People with MS had an increased risk for bladder, brain and cervical cancers compared with people without MS, according to a new study in Neurology, the medical journal of the American Academy of Neurology.

A first-in-human clinical trial will assess the safety of a personalized vaccine to treat diffuse hemispheric glioma, an aggressive brain tumor.